Celadon Pharmaceuticals Regulatory News (CEL)

18 Jul 2007 07:00

Celsis International PLC18 July 2007 CELSIS INTERNATIONAL PLC ("Celsis", "the Company" or "the Group") ANNUAL INFORMATION UPDATE 18 July 2007: Celsis International plc, the life sciences products andlaboratory services company, is pleased to provide an annual information update,in accordance with the requirements of the Prospectus Rule 5.2. This updaterefers to information that has been published or made available by the Companyto the public over the twelve months preceding this announcement. To avoid astatement of unnecessary length information is referred to in this update ratherthan included in full. In accordance with Rule 5.2.7 of the Prospectus Rules, the information referredto in this update was up to date at the time the information was published butsome information may now be out of date. This annual information update doesnot constitute an offer of securities addressed to any person and should not berelied on by any person. 1. Announcements made via the Regulatory News Service ("RNS"), a RegulatoryInformation Service ("RIS"). Date of Publication Regulatory Headline 6 June 2006 Notice of results14 June 2006 Final results14 June 2006 Acquisition16 June 2006 Doc re. acquisition7 July 2006 Annual report and accounts7 July 2006 Annual information update11 July 2006 EGM statement26 July 2006 AGM statement26 July 2006 Result of AGM31 July 2006 Share options1 August 2006 Holding in company30 August 2006 Holding in company BARC11 September 2006 Holding in company BARC19 September 2006 Goodwill tax benefit on acquisition of IVT28 September 2006 Preclose trading update25 October 2006 Notice of results2 November 2006 Holding in company BARC8 November 2006 Interim results17 November 2006 Director/pdmr shareholding22 November 2006 Holding in company BARC15 December 2006 Holding in company BARC24 January 2007 Treasury stock1 February 2007 Total voting rights5 February 2007 Holding in company BARC6 March 2007 Holding in company9 March 2007 Holding in company16 March 2007 Holding in company BARC20 March 2007 Holding in company HBOS28 March 2007 Trading update19 April 2007 Holding in company HBOS15 May 2007 Appointments16 May 2007 Notice of results20 June 2007 Final results5 July 2007 Holding in company BARC9 July 2007 Annual report and accounts Copies of all announcements can be obtained from the Regulatory News Service of the London Stock Exchange. 2. Documents filed at Companies House The documents listed below were filed with the Registrar of Companies in Englandand Wales on or around the dates indicated. Copies of these documents can beobtained from Companies House. Date Document type Description 26 June 2006 363 Annual Return18 July 2006 287 Change in situation or address of registered office27 July 2006 AA Report and Accounts2 July 2007 288a Appointment of new Non Executive Director, Peter Jensen2 July 2007 288a Appointment of new Non Executive Director Nicholas Badman 3. Documents sent to Shareholders The documents listed below have been despatched by the Company to holders of itssecurities on or around the following dates. Date Description 5 July 2007 2007 Annual Report and Accounts5 July 2007 Notice of Annual General Meeting28 November 2006 2006 Interim Report 4. Documents submitted to the UK Listing Authority Copies of the following documents have been submitted to the UK ListingAuthority for inspection at their Document Viewing Facility on or around thefollowing dates and can be obtained from the Company Secretary, CelsisInternational plc, 1010 Cambourne Business Park, Cambourne, Cambridge, CB23 6DP. Date Description 5 July 2007 2007 Annual Report and Accounts5 July 2007 Notice of Annual General Meeting28 November 2006 2006 Interim Report Enquiries:Celsis International plc Tel: 01223 598 428Christian Madrolle, Company SecretaryJenny Parsons, Corporate CommunicationsFinancial Dynamics Tel: 020 7831 3113 Ben AtwellDavid Yates Notes to editors Celsis International plc Celsis International plc is a world leading provider of innovative life scienceproducts and laboratory services to the pharmaceutical, biopharmaceutical, andconsumer products industries through its three business areas; rapid detection,analytical and drug development services and ADME-Tox in vitro technologies.The company is listed on the London Stock Exchange (CEL.L). Each division of Celsis International plc has the capacity to deliversubstantial time and cost savings to its customers, in addition to ensuringproduct quality and safety for consumers. Using proprietary technology, theCelsis Rapid Detection division provides diagnostic systems for the rapiddetection of contamination. These systems provide significant economic value byreducing the time it takes to test and release raw materials, in process andfinished goods to market. Celsis Analytical Services division provides costeffective outsourced laboratory testing services to pharmaceutical andbiopharmaceutical companies. Its comprehensive service offerings include a fullspectrum of laboratory services from drug development and discovery toanalytical chemistry and biological sciences to stability storage and testing.Celsis In Vitro Technologies (Celsis IVT) supplies in vitro testing products tothe pharmaceutical and biotechnology industries. IVT's in vitro products screendrug compounds early in the discovery process, thereby reducing the time andcost of drug development. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange